Next Article in Journal
Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
Next Article in Special Issue
Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis
Previous Article in Journal
Extracellular Vesicles Derived from Kefir Grain Lactobacillus Ameliorate Intestinal Inflammation via Regulation of Proinflammatory Pathway and Tight Junction Integrity
Previous Article in Special Issue
Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 8
Issue 11
10.3390/biomedicines8110523
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Blood Neurofilament Light Chain: The Neurologist’s Troponin?

Biomedicines 2020, 8(11), 523; https://doi.org/10.3390/biomedicines8110523
by Simon Thebault 1,*, Ronald A. Booth 2 and Mark S. Freedman 1,*
Reviewer 1: Anonymous
Reviewer 2:
Tunde Csepany
Biomedicines 2020, 8(11), 523; https://doi.org/10.3390/biomedicines8110523
Submission received: 4 November 2020 / Revised: 17 November 2020 / Accepted: 18 November 2020 / Published: 21 November 2020
(This article belongs to the Special Issue Multiple Sclerosis: Diagnosis and Treatment II)

Round 1

Reviewer 1 Report

In this paper the authors explain why the light chain neurofilament (NfL) dosage in the blood can be useful in multiple sclerosis.
We would welcome references to the diagnostic markers currently in use, even if  they are unsatisfactory, and to possible studies in experimental diseases. What other markers could the NfL dosage be associated with? Is there information on any correlation with inflammatory markers?


Other comments in detail:
1) The title should be changed to indicate that the study is about Multiple Sclerosis;
2) figure 1 needs to be adjusted;
3) line 71, after themselves, put a reference.
4) line 71: clarify what "these antibodies" refers to
5) line 102: write fluorescent, instead of florescent.

Author Response

Many thanks: Please see our response attached

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript is a review that summarizes the physiology and pathophysiology of neurofilaments, the technic of measurement of blood levels of neurofilament light chain and clinical relevance. The topic of the manuscript is important, regarding the continuous development of these measurements in clinical trials. The manuscript is well written.

I only have a couple of minor comments and suggestions:

Figure 1 requires slight modification, because parts of it are not visible.

The key element of this manuscript is the discussion of NFL, as it becomes a potential biomarker to predict disease progression and response to treatment in MS. What is the suggested frequency of monitoring of these levels to evaluate the efficacy of DMT in MS?

The authors would increase the value/utility of this paper if they added extra information to data of the blood levels of NFL, (duration of treatment, change in NfL concentration), including in a Table, because  some of papers cited (69-72) can not be found in PubMed.

Author Response

Many thanks for your comments

Please find our responses attached

 

Author Response File: Author Response.pdf

Back to TopTop